Share this article MUMBAI, Feb. 12, 2021 /PRNewswire/ -- Glenmark's consolidated sales rises by 3.88% to Rs. 27,605.07 Mn. in Q3 FY 2020-21 Consolidated EBITDA rises by 20.45% to Rs. 5300.72 Mn. in Q3 FY 2020-21 Highlights for Q3 FY 2020-21 India Business grew by 11.82% to Rs. 8,821.19 Mn. Europe Business grew by 1.42% to Rs. 3,133.29 Mn. US Business experienced sales decline of (2.43%) to Rs. 7,803.87 Mn. API Business grew by 22.09% to 3,200.70 Mn. Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the third quarter ended December 31 of the financial year 2020-21. For the third quarter of FY 2020-21, Glenmark's consolidated sales was at Rs. 27,605.07 Mn. as against Rs. 26,574.51 Mn. recording an increase of 3.88 %.